MODERN VIEW ON ETIOLOGY, PATHOGENESIS AND TREATMENT OF CHRONIC PELVIC PAIN SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The manuscript presents the analysis of scientific manuscripts written by Russian and foreign researchers devoted to chronic pelvic pain syndrome (CPPS) studies. In spite of widespread disease, there is no clear understanding on etiopathogenetic mechanisms of CPPS development and it is shown that besides infectious process cardiovascular, neuronal, locomotor, endocrine and immune systems are involved into pathological process of CPPS. Mentioned factors complicate the doctors’ task on effective therapy choice and stress the reasonability of complex approach to CPPS treatment. Combination drug containing affinity purified antibodies to endothelial NO-synthase and prostate-specific antigen in released-active form influences different pathogenetic mechanisms of CPPS and thereby reveals pronounced clinical efficacy.

Full Text

Restricted Access

About the authors

A. Z Vinarov

I.M. Sechenov First Moscow State Medical University

Email: avinarov@maiI.ru
Dr.Med.Sci., Professor and Leading Researcher at the Department of Urology Moscow, Russia

References

  1. Krieger J.N., Lee S.W., Jeon J., Cheah P.Y., Liong M.L., Riley D.E. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31(1):85-90. doi: 10.1016/j.ijantimicag.2007.08.028
  2. Potts J.M. Male Pelvic Pain: Beyond Urology and Chronic Prostatitis. Current Rheumatology Reviews. 2016; 2:27-39.
  3. Nickel J.C., Roehrborn C.G., O’Leary M.P., Bostwick D.G., Somerville M.C., Rittmaster R.S. The relationship between prostateinflammation and lower urinary tract symptoms: examination of baseline data from the reduce trial. Eur Urol. 2008;54:1379-1384. Doi: 10.1111/j. 1464-410X.2003.04766.x
  4. Pontari M., Giusto L. New developments in the diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome. Curr. Opin. Urol. 2013;23:565-569. doi: 10.1097/MOU.0b013e3283656a55.
  5. Krieger J.N., Nyberg L. Jr., Nickel J.C. NIH consensus definition and classification ofprostatitis. JAMA. 1999;282:236-237.
  6. Magri V., Marras E., Restelli A., Wagenlehner F.M., Perletti G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med. 2015;9(3):658-666. doi: 10.3892/etm.2014.2152.
  7. Mahal B.A., Cohen J.M., Allsop S.A., Moore J.B., Bhai S.F., Inverso G., Dimitrakoff J.D. The role of phenotyping in chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2011;12:297-303. Doi:10.1007/ s11934-011-0196-y.
  8. Schaeffer A.J. Epidemiology and evaluation of chronic pelvic pain syndrome in men. Int J Antimicrob Agents. 2008;31(1): 108-111. doi: 10.1016/j.ijantimicag.2007.08.027.
  9. Fall M., Baranowski A.P., Fowler C.J., Lepinard V., Malone-Lee J.G., Messelink E.J., Oberpenning F., Osborne J.L., Schumacher S. European Association of Urology. EAU guidelines on chronic pelvic pain. Eur Urol. 2004;46(6):681-689. doi: 10.1016/j.eururo.2004.07.030.
  10. Rees J., Abrahams M., Doble A., Cooper A. Prostatitis Expert Reference Group (PERG) Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509-25. doi: 10.1111/bju.13101. Epub 2015 Jun 16.
  11. Pontari M.A., McNaughton-Collins M., O’leary M.P., Calhoun E.A., Jang T., Kusek J.W., Landis J.R., Knauss J., Litwin M.S., CPCRN Study G. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int. 2005;96:559-565. doi: 10.1111/j.1464-410X.2005.05684.x.
  12. Magri V., Wagenlehner F.M., Marras E., VAN Till J.W., Houbiers J., Panagopoulos P., Petrikkos G.L., Perletti G. Influence of infection on the distribution patterns of NIH-Chronic Prostatitis Symptom Index scores in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS). Exp Ther Med. 2013;6(2):503-508. doi: 10.3892/etm.2013.1174.
  13. Rodriguez M.A., Afari N., Buchwald D.S. National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain. Evidence for overlap between urological and nonurological unexplained clinical conditions. J. Urol. 2009;182: 2123-2131. doi: 10.1016/j.juro.2009.07.036.
  14. Ku J.H., Kim S.W., Paick J.S. Epidemiologic risk factors for chronic prostatitis. Int J Androl. 2005;28:317-327. doi: 10.1111/j.1365-2605.2005.00560.x.
  15. Shin J.H., Lee G. Seasonal changes in symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome: a seasonal follow-up study. Scand J Urol. 2014;48(6):533-7. doi: 10.3109/21681805.2014.936496.
  16. Herati A.S., Shorter B., Srinivasan A.K., Tai J., Seideman C., Lesser M., Moldwin R.M. Effects of foods and beverages on the symptoms of chronic prostatitis/chronic pelvic pain syndrome. Urology. 2013;82:1376-80. doi: 10.1016/j.urology.2013.07.015.
  17. ChenX., Hu C., Peng Y., Lu J., Yang N.Q., Chen L., Zhang G.Q., Tang L.K., Dai J.C. Association of diet and lifestyle with chronic prostatitis/ chronic pelvic pain syndrome and pain severity: a case-control study Prostate Cancer and Prostatic Diseases. 2016; 19,92-99. Doi: 10.1038/ pcan.2015.57.
  18. Zhang R., Sutcliffe S., Giovannucci E., Willett W.C., Platz E.A., Rosner B.A., Dimitrakoff J.D., Wu K. Lifestyle and Risk of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in a Cohort of United States Male Health Professionals. J Urol. 2015; 194(5) : 1295-1300. doi: 10.1016/j.juro.2015.05.100.
  19. Bowen D.K., Dielubanza E., Schaeffer A.J. Chronic bacterial prostatitis and chronic pelvic pain syndrome. BMJ Clin Evid. 2015;27.
  20. Nickel J.C., Alexander R.B., Schaeffer A.J., Landis J.R., Knauss J.S., Propert K.J. Chronic Prostatitis Collaborative Research Network Study Group. Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J Urol. 2003;170:818-822. doi: 10.1097/01.ju.0000082252.49374.e9
  21. Ivanov I.B., Kuzmin M.D., Gritsenko V.A. Microflora of the seminal fluid of healthy men and men suffering from chronic prostatitis syndrome. Int J Androl. 2009;32:462-467 doi: 10.1111/j.1365-2605.2008.00878.x.
  22. Nickel J.C., Stephens A., Landis J.R., Chen J., Mullins C., van Bokhoven A., Lucia M.S., Melton-Kreft R., Ehrlich G.D. Search for Microorganisms in Men with Urologic Chronic Pelvic Pain Syndrome: A Culture-Independent Analysis in the MAPP Research Network. J Urol. 2015;194(1):127-35. doi: 10.1016/j.juro.2015.01.037.
  23. Karatas O.F., Turkay C., Bayrak O., Cimentepe E., Unal D. Helicobacter pylori seroprevalence in patients with chronic prostatitis: a pilot study. Scand J Urol Nephrol. 2010;44:91-94. doi: 10.3109/00365590903535981.
  24. Zhou Z., Hong L., Shen X., Rao X., Jin X., Lu G., Li L., Xiong E., Li W., Zhang J., Chen Z., Pan J., Song B. Detection of nanobacteria infection in type III prostatitis. Urology. 2008;71:1091-1095. Doi: 10.1016/j. urology.2008.02.041.
  25. Park H., Sim S.M., Lee G. The presence of Chlamydia is associated with increased leukocyte counts and pain severity in men withchronic pelvic pain syndrome. Urology. 2015;85(3):574-9. Doi: 10.1016/j. urology.2014.11.008.
  26. Xiao J., Ren L., Lv H., Ding Q., Lou S., Zhang W., Dong Z. Atypical microorganisms in expressed prostatic secretion from patients with chronic prostatitis/chronic pelvic pain syndrome: microbiological results from a case-control study. Urol Int. 2013;91(4):410-6. doi: 10.1159/000350934. Epub 2013 Aug 21.
  27. Motrich R.D., Breser M.L., Sanchez L.R., Godoy G.J., Prinz I., Rivero V.E. IL-17 is not essential for inflammation and chronic pelvic pain development in an experimental model of chronic prostatitis/chronic pelvic pain syndrome. Pain. 2016; 157(3):585-597. Doi:10.1097/j. pain.0000000000000405.
  28. Hochreiter W.W., Nadler R.B., Koch A.E., Campbell P.L., Ludwig M., Weidner W., Schaeffer A.J. Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology. 2000;56:1025-1029.
  29. Alexander R.B., Brady F., Ponniah S. Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins.Urology. 1997;50:893- 899. oi: 10.1016/S0090-4295(97)00456-1.
  30. Murphy A.B., Schaeffer A.J., Thumbikat P. Immune mediators of chronic pelvic pain syndrome Nat. Rev. Urol. advance online publication. 2014. doi: 10.1038/nrurol.2014.63.
  31. Watanabe T., Inoue M., Sasaki K., Araki M., Uehara S., Monden K., Saika T., Nasu Y., Kumon H., Chancellor M.B. Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. BJU Int. 2011;108:248-251. doi: 10.1111/j.1464-410X.2010.09716.x.
  32. Nickel J.C., Atkinson G., Krieger J.N., Mills I.W., Pontari M., Shoskes D.A., Crook T.J. Preliminary assessment of safety and efficacy in proof-of-concept, randomized Clinical trial of tanezumab for chronic prostatitis/ chronic pelvic pain syndrome. Urology. 2012;80:1105-1110. doi: 10.1016/j.urology.2012.07.035.
  33. Cho D.S., Choi J.B., Kim Y.S., Joo K.J., Kim S.H., Kim J.C., Kim H.W. Heart rate variability in assessment of autonomic dysfunction in patients with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2011;78:1369-1372. doi: 10.1016/j.urology.2011.07.1379.
  34. Shoskes D.A., Prots D., Karns J., Horhn J., Shoskes A.C. Greater endothelial dysfunction and arterial stiffness in men with chronic prostatitis/chronic pelvic pain syndrome a possible link to cardiovascular disease. J Urol. 2011;186:907-910. Doi: http://dx.doi.org/10.1016/j.juro.2011.04.063.
  35. Hetrick D.C., Glazer H., Liu Y.W., Turner J.A., Frest M. Berger R.E. Pelvic floor electromyography in men with chronic pelvic pain syndrome: a case-control study. Neurourol Urodyn. 2006;25:46-49. Doi: 10.1002/ nau.20162.
  36. Farmer M.A., Chanda M.L., Parks E.L., Baliki M.N., Apkarian A.V., Schaeffer A.J. Brain functional and anatomical changes in chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2011;186:117-124. doi: 10.1016/j.juro.2011.03.027.
  37. Woolf C.J. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152:2-15. doi: 10.1016/j.pain.2010.09.030.
  38. Riegel B., Bruenahl C.A., Ahyai S., Bingel U., Fisch M., Löwe B. Assessing psychological factors, social aspects and psychiatric co-morbidity associated with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/ CPPS) in men a systematic review. J Psychosom Res. 2014;77(5):333-50. doi: 10.1016/j.jpsychores.2014.09.012.
  39. Ullrich P.M., Turner J.A., Ciol M., Berger R. Stress is associated with subsequent pain and disability among men with nonbacterial prostatitis/ pelvic pain. Ann Behav Med. 2005;30:112-118. Doi:10.1207/ s15324796abm3002_3.
  40. Hu J.C., Link C.L., McNaughton-Collins M., Barry M.J., McKinlay J.B. The association of abuse and symptoms suggestive of chronic prostatitis/ chronic pelvic pain syndrome: results from the boston area community health survey. J Gen Intern Med. 2007;22:1532-1537. Doi: 10.1007/ s11606-007-0341-y.
  41. Makovey I., Dolinga R., Shoskes D.A. Spousal Revenge Syndrome’description of a new chronic pelvic pain syndrome patient cohort. Can J Urol. 2016;23(1):8176-8178.
  42. Di Franco M., Iannuccelli C., Valesini G. Neuroendocrine immunology of fibromyalgia. Ann N Y Acad Sci. 2010;1193:84-90. doi: 10.1111/j.1749-6632.2009.05344.x.
  43. Lee J.H., Lee S.W. Testosterone and Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Propensity Score-Matched Analysis. J Sex Med. 2016; May 24. pii: S1743-6095(16)30172-2. doi: 10.1016/j.jsxm.2016.04.070.
  44. Nadler R.B., Collins M.M., Propert K.J., Mikolajczyk S.D., Knauss J.S., Landis J.R., Fowler J.E. Jr., Schaeffer A.J., Alexander R.B. Chronic Prostatitis Collaborative Research Network. Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology. 2006;(2):337-42. doi: 10.1016/j.urology.2005.08.031.
  45. Ponniah S., Arah I., Alexander R.B. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate. 2000;44(1):49-54.
  46. Белоусов И.И., Черногубова Е.А., Коган М.И. Роль эндотелиальной дисфункции в патогенезе невоспалительной формы хронического абактериального простатита. Урология. 2013;3 :39-42
  47. Fall M., Baranowski A.P., Elneil S., Engeler D., Hughes J., Messelink E.J., Oberpenning F., de C Williams A. C. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57(1):35-48. doi: 10.1016/j.eururo.2009.08.020.
  48. Zongshi Q., Jiani W., Jing Z., Zhishun L. Systematic Review of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Medicine. 2016;11:1-10. doi: 10.1097/MD.0000000000003095.
  49. Polackwich A.S., Shoskes D.A. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer and Prostatic Diseases. 2016;1-7. doi: 10.1038/pcan.2016.8.
  50. Zhang K., Bai W.J., Shang X.J., Xiao Y.X., Liu J.H., Li Z., Deng C.H., Wang H. P. Application of CUA Guidelines on Prostatitis in the management of chronic pelvic pain syndrome: a nationwide survey. Zhonghua Nan Ke Xue. 2013;19(2):127-131.
  51. Touma N.J., Nickel J.C. Prostatitis and chronic pelvic pain syndrome in men. Med Clin North Am. 2011 ;95(1):75-86. Doi: 10.1016/j. mcna.2010.08.019.
  52. Choe H.S., Lee S.J., Han C.H., Shim B.S., Cho Y.H. Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. J Infect Chemother. 2014;20(1):20-5. doi: 10.1016/j.jiac.2013.07.010.
  53. Galley H.F., Nelson S.J., Dubbels A.M., Webster N.R. Effect ofciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis. Crit Care Med. 1997;25: 1392-1395.
  54. Yoshimura T., Kurita C., Usami E., Nakao T., Watanabe S., Kobayashi J., Yamazaki F., Nagai H. Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy. 1996;42:459-464. doi: 10.1159/000239480
  55. Sadarangani S.P., Estes L.L., Steckelberg J.M. Non-anti-infective effects of antimicrobials and their clinical applications: a review. Mayo Clin Proc. 2015;90:109-127. doi: 10.1074/jbc.M115.671222.
  56. Schwinn D.A., Roehrborn C.G. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15:193-199. doi: 10.1111/j.1442-2042.2007.01956.x.
  57. Krieger J.N., McNaughton-Collins M., Anderson R.U., Pontari M., Shoskes D.A., Litwin M.S., Alexander R.B., White P.C., Berger R., Nadler R., O’Leary M., Liong M.L., Zeitlin S., Chuai S., Landis J.R., Kusek J.W., Nyberg L.M., Schaeffer A.J. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med. 2008;359:2663. doi: 10.1056/NEJMoa0803240.
  58. Michel M.C. Alpha1-adrenoceptors and ejaculatory function. Br J Pharmacol. 2007;152:289-290. doi: 10.1038/sj.bjp.0707369.
  59. Thakkinstian A., Attia J., Anothaisintawee T., Nickel J.C. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2012;110(7):1014-22. doi: 10.1111/j.1464-410X.2012.11088.x.
  60. Zhao W.P., Zhang Z.G., Li X.D., Yu D., Rui X.F., Li G.H., Ding G.Q. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (category IIIA). Braz J Med Biol Res. 2009;42:963-967.
  61. Bates S.M., Hill V.A., Anderson J.B., Chapple C.R., Spence R., Ryan C., Talbot M.D. A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2007;99:355-359. doi: 10.1111/j.1464-410X.2007.06667.x
  62. Papandreou C., Skapinakis P., Giannakis D., Sofikitis N., Mavreas V. Antidepressant drugs for chronic urological pelvic pain: an evidence-based review. Adv Urol. 2009;2009:797031. doi: 10.1155/2009/797031.
  63. Giannantoni A., Porena M., Gubbiotti M., Maddonni S., Di Stasi S.M. The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2014;83(2):400-405. doi: 10.1016/j.urology.2013.09.024.
  64. Xia D., Wang P., Chen J., Wang S., Jiang H. Fluoxetine ameliorates symptoms of refractory chronic prostatitis/chronic pelvic pain syndrome. Chin Med J (Engl). 2011;124(14):2158-2161.
  65. Kaplan S.A., Volpe M.A., Te A.E. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/ chronic pelvic pain syndrome. J Urol. 2004; 171( 1) :284-8. doi: 10.1097/01.ju.0000101487.83730.80.
  66. Nickel J.C., Downey J., Pontari M.A., Shoskes D.A., Zeitlin S.I. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy offinasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int. 2004;93(7):991-995. doi: 10.1111/j.1464-410X.2003.04766.x.
  67. Murphy A.B., Nadler R.B. Pharmacotherapy strategies in chronic prostatitis/chronic pelvic pain syndrome management. Expert Opin Pharmacother. 2010;11:1255-1261. doi: 10.1517/14656561003709748.
  68. Herati A.S., Moldwin R.M. Alternative therapies in the management of chronic prostatitis/chronic pelvic pain syndrome. World J Urol. 2013. doi: 10.1007/s00345-013-1097-0.
  69. Tsunemori H., Sugimoto M., Xia Z., Taoka R., Oka M., Kakehi Y. Effect of the phytotherapeutic agent Eviprostat on inflammatory changes and cytokine production in a rat model of nonbacterial prostatitis. Urology. 2011;77(6):1507. doi: 10.1016/j.urology.2011.02.017.
  70. Liao Y.R., Lin J.Y. Quercetin intraperitoneal administration ameliorates lipopolysaccharide-induced systemic inflammation in mice. Life Sci. 2015;137:89-97. doi: 10.1016/j.lfs.2015.07.015.
  71. Wagenlehner F.M., Bschleipfer T., Pilatz A., Weidner W. Pollen extract for chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am. 2011:38(3):285-292. doi: 10.1016/j.ucl.2011.04.004.
  72. Goodarzi D., Cyrus A., Baghinia M.R., Kazemifar A.M., Shirincar M. The Efficacy of Zinc for Treatment of Chronic Prostatitis Acta Med Indones. 2013;45(4):259-264.
  73. Cui D., Han G., Shang Y., Mu L., Long Q., Du Y. The effect of chronic prostatitis on zinc concentration of prostatic fluid and seminal plasma: a systematic review and meta-analysis. Curr Med Res Opin. 2015;31(9):1763-9. doi: 10.1185/03007995.2015.1072707.
  74. Prasad A.S. Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health Front Nutr. 2014;1:14. doi: 10.3389/fnut.2014.00014.
  75. Haase H., Overbeck S., Rink L. Zinc supplementation for the treatment or prevention of disease: Current status and future perspectives. Experiment Gerontol. 2008;43:394-408. doi: 10.1016/j.exger.2007.12.002.
  76. Malm J., Hellman J., Hogg P., Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate. 2000;45(2):132-139.
  77. Xiao L., Cheng J., Dai J., Zhang D. Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats. Pain Med. 2011;12:1385-1394. doi: 10.1111/j.1526-4637.2011.01182.x.
  78. Jhang J.F., Kuo H.C. Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by Onabotulinumtoxin A Injection Toxins (Basel). 2015;7(6):2232-2250. doi: 10.3390/toxins7062232.
  79. Mishra V.C., Browne J., Emberton M. Role of repeated prostatic massage in chronic prostatitis: a systematic review of the literature. Urology. 2008;72:731-5. doi: 10.1016/j.urology.2008.04.030.
  80. Potts J.M. Chronic pelvic pain syndrome: a non-prostatocentric perspective. World J Urol. 2003;21(2):54-6. doi: 10.1007/s00345-003-0327-2.
  81. Эпштейн О.И. Релиз-активность - от феномена до создания новых лекарственных средств. Бюллетень экспериментальной биологии и медицины 2012;7:62-67
  82. Эпштейн О.И. Сверхмалые дозы (история одного исследования). М.: Изд-во РАМН. 2008; 336 c
  83. Zhang Y., Zheng T., Tu X., Chen X., Wang Z., Chen S., Yang Q., Wan Z., Han D., Xiao H., Sun X., Deng C. Erectile Dysfunction in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Outcomes from a MultiCenter Study and Risk Factor Analysis in a Single Center. PLoS One. 2016;11(4):e0153054. doi: 10.1371/journal.pone.0153054.
  84. Blick C., Ritchie R.W., Sullivan M.E. Is Erectile Dysfunction an Example of Abnormal Endothelial Function? Curr Vasc Pharmacol. 2016;14(2): 163-167.
  85. Цыбденов А.Г. Клиническая эффективность препаратов «Афала» и «Импаза» в лечении гиперплазии предстательной железы в сочетании с эректильной дисфункцией. Вестник Бурятского Госуниверситета. 2009; 12: 129-130
  86. Яковец Я.В., Неймарк А.И., Яковец Е.А. Возможности и показания к проведению комплексной терапии в лечении больных доброкачественной гиперплазией простаты (ДГП), осложненной эректильной дисфункцией. Х Региональная научно-практическая конференция урологов Западной Сибири «Актуальные вопросы диагностики и лечения урологических заболеваний». Барнаул. 2011;182-184
  87. Усупбаев А.Ч., Хакимходжаев З.Ш., Евсюков В.Н. Современные взгляды на лечение, профилактику и повышение качества жизни больных с хроническим простатитом: методические рекомендации. Бишкек. 2012;54 с

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies